Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

INB 200

Next Previous
Drug Profile

INB 200

Alternative Names: Allogeneic gamma-delta T-cells immunotherapies - IN8bio; CliniMACS Alpha Beta T-Cell Depletion System - IN8bio; CliniMACS-Prodigy - IN8bio; DeltEx DRI - IN8bio; DeltEx Drug Resistant Immunotherapy - IN8bio; EAGD T-cell infusion; INB-200

Latest Information Update: 08 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Incysus
  • Developer IN8bio
  • Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Glioblastoma

Most Recent Events

  • 08 May 2025 Phase-I development in Glioblastoma (Combination therapy, Second-line therapy or greater) is ongoing in USA (Intrathecal, Infusion) (NCT04165941)
  • 28 Apr 2025 No recent reports of development identified for phase-I development in Glioblastoma(Combination therapy, Second-line therapy or greater) in USA (Intrathecal, Infusion)
  • 25 Nov 2024 Efficacy and adverse events data from a phase I trial in Glioblastoma released by IN8bio

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top